Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
The Motley Fool9d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline ... top-selling weight loss drugs. In a 72-week study ...
Yahoo Finance12d
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug ... approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks associated with chronic kidney disease (CKD). The Danish drugmaker’s popular weight loss ...
USA Today3d
Drug industry groups target Hims & Hers Super Bowl ad touting weight loss drug
Although the ad does not identify the medication, Hims & Hers offers compounded versions of the weight-loss drug semaglutide, which was developed by Novo Nordisk ... are not FDA approved and ...
AOL9d
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this ... two top-selling weight loss drugs.
NBC Washington13d
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
The Food and Drug Administration approved ... Novo Nordisk's drugs with the active ingredient semaglutide for the second cycle of Medicare drug price negotiations. That includes Ozempic, its ...